JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
· Financial Post
Boehringer Ingelheim today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). It is the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects approved in these indications. The decision makes Japan the fourth market worldwide to approve nerandomilast and represents an important new treatment option for people with these progressive and life‑limiting fibrosing lung conditions. Read More
Visit tr-sport.click for more information.